Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 30:10:584766.
doi: 10.3389/fonc.2020.584766. eCollection 2020.

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

Cong Lu  1   2   3 , Jiang Zhu  1   2   3 , Xiangjun Chen  1   2   3 , Yanjie Hu  1   2   3 , Wei Xie  1   2   3 , Junxia Yao  1   2   3 , Shiang Huang  1   2   3
Affiliations

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

Cong Lu et al. Front Oncol. .

Abstract

The role of CXC chemokine receptors in tumors has been an increasingly researched focus in recent years. However, significant prognostic values of CXCR members in acute myeloid leukemia are yet to be explored profoundly. In this study, we firstly made an analysis of the relationship of CXCR family members and AML using samples from TCGA. Our results suggested that transcriptional expressions of CXCRs serve an important role in AML. CXCR transcript expressions, except CXCR1 expression, were significantly increased in AML. It displayed the expression pattern of CXCR members in different AML subtypes according to FAB classification. The correlations of CXCR transcript expression with different genotypes and karyotypes were also present. High CXCR2 expression was found to have a significantly worse prognosis compared with that of low CXCR2 expression, and CXCR2 was also found to be an independent prognostic factor. We also established a CXCR signature to identify high-risk subgroups of patients with AML. It was an independent prognostic factor and could become a powerful method to predict the survival rate of patients.

Keywords: CXC chemokine receptor; FAB subtypes; acute myeloid leukemia; gene signature; prognostic role; risk stratification.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The mRNA expression from GEPIA. (A) CXCRs between AML and normal samples. (*P < 0.05). (B) CXCR2 expression profile across all tumor samples and paired normal tissues.
Figure 2
Figure 2
The transcriptional expressions of CXCRs in AML subtype according to FAB classification.
Figure 3
Figure 3
Analysis of prognostic gene expressions between the mutant group and the wild-type group. (A) FLT3 mutation. (B) NPM1 mutation. (C) IDH1 mutation. (D) cytogenetic karyotype.
Figure 4
Figure 4
The expressions of (A) CXCR1, (B) CXCR2, and (C) CXCR6 between AML low and medium-high risk group.
Figure 5
Figure 5
The prognostic values of CXCR family members in AML patients.
Figure 6
Figure 6
The forest plot for the gene signature model and Concordance Index.
Figure 7
Figure 7
The prognostic values of CXCR signature. (A) The survival curves of low- and high- risk group. (B) The heatmap of gene signature. (C) The risk score of AML patients in two groups.
Figure 8
Figure 8
The AUC corresponding to 1, 2, and 3 years of CXCR signature using K-M plot.
Figure 9
Figure 9
The PPI of CXCR family members and their neighbor genes (A) the PPI network analyzed by String. (B) The hub genes analyzed by Cytoscape.
Figure 10
Figure 10
The functions of CXCRs and neighborhood genes predicted by GO and KEGG analysis by String. (A) Biological Process. (B) Cellular Component. (C) Molecular Function. (D) KEGG enrichment.
Figure 11
Figure 11
Kaplan-Meier survival curves in validation cohort using TARGET database. (A) CXCR2. (B) CXCR gene signature.
See this image and copyright information in PMC

References

    1. Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood (2017) 129(12):1627–35. 10.1182/blood-2016-10-696039 - DOI - PubMed
    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med (2015) 373(12):1136–52. 10.1056/NEJMra1406184 - DOI - PubMed
    1. Balkwill FR. The chemokine system and cancer. J Pathol (2012) 226(2):148–57. 10.1002/path.3029 - DOI - PubMed
    1. Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy. Front Immunol (2019) 10:379. 10.3389/fimmu.2019.00379 - DOI - PMC - PubMed
    1. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett (2008) 267(2):226–44. 10.1016/j.canlet.2008.04.050 - DOI - PubMed

LinkOut - more resources